NCT00848029已完成3 期
Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules
Novartis Vaccines1 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2008年11月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- Evaluation of antibody response to a monovalent inactivated influenza vaccine adjuvanted with MF59 and uses a surface antigen from a potential pandemic homologous virus strain candidate (H5N1).
研究概览
简要总结
The present study will evaluate the immunogenicity, safety and immunogenicity of two doses of monovalent inactivated influenza vaccine that is adjuvanted with MF59C.1 (MF59) and uses a surface antigen from a potential pandemic virus strain candidate (H5N1) in Adult Subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects aged 18 to 60 years of age who are mentally competent and who have signed an informed consent form after having received a detailed explanation of the study protocol;
- •In good health as determined by:
- •Medical history,
- •Physical examination,
- •Clinical judgment of the Investigator;
- •Able to understand and comply with all study procedures and to complete study diaries, can be contacted, and will be available for all study visits.
排除标准
- •Previous receipt of any H5 vaccine;
- •Receipt of another investigational agent within 4 weeks, or before completion of the safety follow-up period in another study, whichever is longer, prior to enrollment and unwilling to refuse participation in another clinical study through the end of the study;
- •Experienced any acute disease or infection requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis is acceptable) within the past 7 days;
- •Experienced fever (defined as axillary temperature 38.0°C) within 3 days prior to Visit 1;
- •Pregnant or breastfeeding;
- •Females of childbearing potential who refuse to use an acceptable method of birth control for the duration of the study. Adequate contraception is defined as hormonal (e.g., oral, injection, transdermal patch, implant, cervical ring), barrier (e.g., condom with spermicide or diaphragm with spermicide), intrauterine device (e.g., IUD), or monogamous relationship with vasectomized partner who has been vasectomized for 6 months or more prior to the subject's study entry;
- •Any serious disease, such as:
- •Autoimmune disease,
- •diabetes mellitus,
- •chronic pulmonary disease,
- •acute or progressive hepatic disease,
- •acute or progressive renal disease;
- •Surgery planned during the study period;
- •Bleeding diathesis;
- •Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the study vaccine;
- •History of any neurological symptoms or signs following administration of any vaccine, or anaphylactic shock following administration of any vaccine;
- •Known or suspected impairment/alteration of immune function, for example, resulting from:
- •Receipt of immunosuppressive therapy (any corticosteroid therapy
- •Receipt of immunostimulants,
- •High risk for developing an immunocompromising disease
研究组 & 干预措施
1
Experimental
干预措施: Monovalent inactivated influenza vaccine (Biological)
结局指标
主要结局
Evaluation of antibody response to a monovalent inactivated influenza vaccine adjuvanted with MF59 and uses a surface antigen from a potential pandemic homologous virus strain candidate (H5N1).
时间窗: 6 months
次要结局
- Evaluation of safety of the monovalent inactivated influenza vaccine that is adjuvanted with MF59C.1 (MF59) and uses a surface antigen from a potential pandemic virus strain candidate (H5N1) in Adult Subjects.(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly SubjectsPrepandemic Influenza VaccineNCT00841646Novartis Vaccines343
已完成
2 期
Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of AgeInfluenzaNCT00397215GlaxoSmithKline437
进行中（未招募）
1 期
Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and AboveRespiratory Syncytial Virus (RSV)NCT06642558MAXVAX Biotechnology Limited Liability Company522
已完成
2 期
Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy AdultsInfluenzaNCT00328107Protein Sciences Corporation459
已完成
1 期
A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge ModelMalariaNCT01397227Crucell Holland BV36